Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.45 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8510497 | 0.85 | KMT2A (0.49) | KMT2AAPPCYP1A2HIF1ACSNK2A2 | |
| SCHEMBL6120513 | 0.84 | KMT2A (0.48) | KMT2AAPPCYP1A2HIF1ACSNK2A2 | |
| SCHEMBL618092 | 0.84 | MAPT (0.54) | KMT2AAPPMAPTALDH1A1KDM4E | |
| SCHEMBL135158 | 0.84 | KDM4E (0.60) | KMT2AHIF1AMAPTALDH1A1HPGD | |
| SCHEMBL9597948 | 0.83 | RAB9A (0.55) | KMT2AMAPTALDH1A1KDM4EHSD17B10 | |
| SCHEMBL8513642 | 0.79 | KMT2A (0.44) | KMT2AAPPCYP1A2HIF1ACSNK2A2 | |
| SCHEMBL737833 | 0.77 | KMT2A (0.49) | KMT2AAPPCYP1A2HIF1ACSNK2A2 | |
| SCHEMBL135038 | 0.77 | APP (0.48) | KMT2AAPPCYP1A2HIF1AMAPT | |
| SCHEMBL626753 | 0.76 | MAPT (0.52) | KMT2AMAPTABCC1ABCC2ALDH1A1 | |
| SCHEMBL8510627 | 0.76 | CSNK2A2 (0.45) | KMT2ACSNK2A2CSNK2BCSNK2A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430029-B1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2018-01-10 | — | — | EP | claimed |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2014-10-02 | — | — | US | claimed |
| WO-2010130842-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-11-18 | — | — | WO | claimed |
| EP-2430029-B1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2018-01-10 | — | — | EP | disclosed |
| EP-2640729-B1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-9499563-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-11-22 | — | — | US | disclosed |
| US-9447116-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20140315927-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2014-10-02 | — | — | US | disclosed |
| US-8809363-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-8785638-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120136023-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| WO-2010130842-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLRMT, MAVS | KMT2A 2301/4885APP 3901/4885CYP1A2 3978/4885 |
| US-20120136023-A1 | Inhibitors of HIV Replication | RTF2, POLRMT, MAVS | KMT2A 2301/4885APP 3901/4885CYP1A2 3978/4885 |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | KMT2A 2903/4885APP 2598/4885CYP1A2 860/4885 |
| US-20140315927-A1 | Inhibitors of HIV Replication | RTF2, POLRMT, MAVS | KMT2A 2301/4885APP 3901/4885CYP1A2 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.